Maryanne Demasi, reports

Maryanne Demasi, reports

Share this post

Maryanne Demasi, reports
Maryanne Demasi, reports
Part 2: Journal ignores evidence of misconduct in ticagrelor studies

Part 2: Journal ignores evidence of misconduct in ticagrelor studies

After publishing two key studies, the journal Circulation has deflected responsibility amid evidence of scientific misconduct—missing data, outcome switching, and authorship irregularities.

Maryanne Demasi, PhD's avatar
Maryanne Demasi, PhD
Jul 08, 2025
∙ Paid
76

Share this post

Maryanne Demasi, reports
Maryanne Demasi, reports
Part 2: Journal ignores evidence of misconduct in ticagrelor studies
22
18
Share

Circulation—one of cardiology’s leading journals and the flagship publication of the American Heart Association—has refused to act on serious concerns raised about two key studies used to promote AstraZeneca’s anti-clotting drug, ticagrelor.

The studies were instrumental in portraying ticagrelor as ‘faster and more potent’ than its cheaper rival, clopidogrel—a message that fuelled its widespread use and cemented its place in clinical guidelines worldwide.

But as detailed in Part 1, both studies contain major irregularities.

An investigation by The BMJ’s Dr Peter Doshi alleged scientific misconduct, citing undisclosed changes to primary endpoints, missing platelet data submitted to the FDA, and serious questions surrounding authorship of the research.

click icon for story

Circulation passes the buck

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Maryanne Demasi
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share